B7-H3, a Checkpoint Molecule, as a Target for Cancer Immunotherapy

International Journal of Biological Sciences - Canada
doi 10.7150/ijbs.41105
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ivyspring International Publisher

Related search

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2

Clinical Cancer Research
Cancer ResearchOncology
2015English

B7-H3 as a Promising Target for Cytotoxicity T Cell in Human Cancer Therapy

Oncotarget
Oncology
2016English

ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy

Current Protein and Peptide Science
MedicineBiochemistryCell BiologyMolecular Biology
2018English

Hsa_circ0021347 as a Potential Target Regulated by B7-H3 in Modulating the Malignant Characteristics of Osteosarcoma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2019English

B7-H4 Expression as a Predictive Biomarker in Human Cervical Cancer Immunotherapy

International Journal of Cancer Studies & Research
2016English

B7-H3, a Potential Therapeutic Target, Is Expressed in Diffuse Intrinsic Pontine Glioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2012English

Ring Finger Protein 43 as a New Target for Cancer Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2004English

The Third Group of the B7-Cd28 Immune Checkpoint Family: HHLA2, TMIGD2, B7x, and B7-H3

Immunological Reviews
AllergyImmunology
2017English

B7-H3 in Cancer – Beyond Immune Regulation

Trends in Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy